Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

teva b.v. - ζολεδρονικό οξύ - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - Φάρμακα για τη θεραπεία ασθενειών των οστών - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. Θεραπεία της νόσου του paget των οστών σε ενήλικες.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sanofi-aventis cyprus ltd (0000003441) 14 charalambou mouskou str., strovolos, 2015 - prochlorperazine maleate - tablets - 5mg - prochlorperazine maleate (0000084026) 5mg - prochlorperazine

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

sanofi-aventis aebe - ΜΟΝΟΗΥΔΡΑ ΖΑΛΕΔΡΟΝΙΚΟΥ ΟΞΕΟΣ - ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ - 5mg/100ml - ineof01470 - zoledronic acid monohydrate - 5.000000 mg - zoledronic acid

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. pharmazac ae Ναούσης 31, Βοτανικός,, 104 47 104 47, Αθήνα 210.3418889-97 - zoledronic acid monohydrate - sol.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ) - 5mg/100ml - zoledronic acid monohydrate 5,33mg - zoledronic acid

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sanofi-aventis cyprus ltd - ΤΟ zoledronic acid monohydrate - solution for infusion - 5mg/100ml - 0165800066 - zoledronic acid monohydrate - 0.0533 mg - zoledronic acid

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

b. braun melsungen a.g, germany carl-braun-strasse 1, 34212 melsungen 0049 56 61 71 2849 - isoleucine; leucine; lysine monohydrate; methionine; phenylalanine; threonine; tryptophan, l-; valine; arginine; histidine hydrochloride; alanine; aspartic acid; glutamic acid; glycine; proline; serine; dextrose(glucose) monohydrate; triglycerides medium chain; soya oil; omega-3-acid triglycerides - inj.em.inf (ΓΑΛΑΚΤΩΜΑ ΓΙΑ ΕΓΧΥΣΗ) - isoleucine 3,284g; leucine 4,384g; lysine monohydrate 3,576g; methionine 2,736g; phenylalanine 4,196g; threonine 2,54g; tryptophan, l- 0,8g; valine 3,604g; arginine 3,78g; histidine hydrochloride 1,752g; alanine 6,792g; aspartic acid 2,1g; glutamic acid 4,908g; glycine 2,312g; proline 4,76g; serine 4,2g; dextrose(glucose) monohydrate 158,4g; triglycerides medium chain 20g; soya oil 16g; omega-3-acid triglycerides 4g - combinations

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

seacross pharma (europe) limited (0000011584) regus dublin airport, skybridge house, dublin, k67 p6k2 - zoledronic acid monohydrate - solution for infusion - 0.05mg/ml - zoledronic acid monohydrate (0165800066) 0.0533mg

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - Κυστική ίνωση - Άλλα προϊόντα του αναπνευστικού συστήματος - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 και 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 και 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

bpl bioproducts laboratory gmbh (0000011488) dornhofstrasse 34, neu-isenburg, 63263 - anti-d immunglobulin - solution for injection - 50mcg/ml - anti-d immunglobulin (8000031029) 500iu - anti-d (rh) immunoglobulin

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

medochemie hellas ae ΠΑΡΑΣ.& ΕΜΠΟΡ.ΦΑΡΜ.& Φ/ΚΩΝ ΠΡ. Δ.Τ. medochemie hellas a.e. Παστέρ 6,, 115 21 115 21, Αθήνα 210.6413160 - clopidogrel - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 75mg/tab - clopidogrel 75mg - clopidogrel